LpxC Inhibitor Synthesis for Gram-Negative Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections, particularly gram-negative infections, lack effective inhibitors for the essential enzyme LpxC, which is crucial in lipid A biosynthesis, leading to inadequate therapeutic options.
Innovation Solution
Development of a potent LpxC inhibitor compound, (S)-1-(3-(5,6-dihydroxypyrimidin-4-yl)-2-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)azetidine-3-carbonitrile, through a multi-step synthetic process involving specific oxidation and reduction reactions, coupling catalysts, and deprotection conditions, targeting gram-negative bacterial strains without affecting gram-positive bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for bacterial infections are used, then existing therapeutic options are available, but effective inhibition of LpxC enzyme is not achieved
Solution Approach 1:
The patent modifies the chemical structure of LpxC inhibitors by changing parameters such as introducing specific functional groups (carboxylic acid, hydroxyl, amino), adjusting molecular weight, and modifying stereochemistry to achieve effective inhibition against gram-negative bacteria while maintaining selectivity
Solution Approach 2:
The invention creates composite molecular structures that combine multiple functional groups and structural motifs to achieve both potent LpxC inhibition and selective activity against gram-negative bacteria, thereby resolving the contradiction between effectiveness and adaptability
2Reliability
If LpxC inhibitor compound is developed, then selective inhibition of gram-negative bacteria is achieved, but complex multi-step synthetic process is required
Solution Approach 1:
The synthesis process is divided into discrete steps: (1) formation of the core azetidine structure, (2) introduction of the pyrimidine moiety, (3) addition of the phenyl-ethynyl group, (4) formation of the carboxylic acid group, and (5) final optimization steps. Each step builds a specific functional element, allowing for systematic development of the selective inhibitor
Solution Approach 2:
Protecting groups are introduced in advance during the synthesis process to prevent unwanted reactions at specific stages, and are subsequently removed in final deprotection steps. This preliminary action allows for controlled building of the complex molecule with specific functional groups in the correct positions
3Reliability
If potent LpxC inhibition is achieved, then bacterial cell lines are effectively targeted, but gram-positive bacteria are also affected
Solution Approach 1:
The patent introduces specific functional groups and structural features (such as the carboxylic acid at a specific position, hydroxyl groups, and stereochemical configurations) that create local chemical properties selective for gram-negative bacteria. This local quality differentiation allows the inhibitor to target LpxC in gram-negative bacteria while sparring gram-positive bacteria, thereby reducing harmful effects on the latter
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound exhibits MIC values of <1 μg/mL against E. coli and K. pneumoniae, demonstrating its effectiveness as a selective inhibitor of gram-negative bacterial cell lines while sparing gram-positive bacteria, thus offering a promising therapeutic approach for urinary tract infections and other gram-negative infections.
Implementation Method 1
contacting the compound of Formula 14 with a suitable oxidation reagent system in a suitable solvent to provide a compound of Formula 15
Implementation Method 2
contacting a compound of Formula 13 with a suitable borohydride reagent in a suitable solvent to provide the compound of Formula 14
Data Source
AI summary
Provided herein is an LpxC inhibitor compound, as well as methods of making and pharmaceutical compositions comprising said compound, and methods of use thereof in the treatment of disease that would benefit from treatment with an LpxC inhibitor, including gram-negative bacterial infections such as urinary tract infections and the like.